RC48 plus radiation for HER2-positive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a targeted drug (RC48) combined with radiation therapy for a specific type of bladder cancer that has not invaded the muscle layer. It may be an option if your cancer has a high amount of HER2 protein and you cannot have standard BCG treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a procedure (TURBT) to remove your bladder tumor, and your doctor saw no visible tumor left.
- Your cancer is non-muscle invasive and is considered high or very high risk.
- You cannot or will not receive BCG therapy (a standard treatment for bladder cancer).
- Your tumor cells have a high amount of HER2 protein (2+ or 3+ on a test).
- You are generally able to do your daily activities (ECOG score 0 or 1).
- Your heart, bone marrow, liver, and kidneys are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called RC48-ADC for people with a type of early-stage bladder cancer that has not responded to the standard BCG treatment. The drug targets a protein called HER2 on cancer cells, which may help stop the cancer from growing.
This Phase 2 study tests RC48, an antibody-based drug, combined with gemcitabine to treat high-risk, non-muscle invasive bladder cancer that has not responded well to BCG or cannot receive BCG. It may help shrink tumors and reduce the chance of the cancer coming back.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
This trial tests a combination of two drugs—an antibody-drug conjugate (Disitamab Vedotin) and an immunotherapy (Toripalimab)—given for different lengths of time to treat muscle-invasive bladder cancer. The goal is to preserve the bladder while controlling the cancer.
This trial tests whether injecting a targeted drug (RC48) directly into the bladder after surgery for upper urinary tract cancer can help prevent recurrence in patients whose tumors have high levels of a protein called HER2. The drug is designed to attack cancer cells while minimizing harm to healthy cells.
This trial tests a combination of immunotherapy (toripalimab), a targeted antibody-drug (RC48-ADC), and radiation to try to save the bladder in people with HER2-positive muscle-invasive bladder cancer. The goal is to see if this approach can shrink or eliminate the cancer without needing surgery to remove the bladder.
Hear when a new HER2-expressing High-risk or Very High-risk NMIBC Without Visible Foci of Disease After TURBT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.